A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2014
At a glance
- Drugs Trametinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
- 24 Jan 2013 Results will be presented at the 2013 ASCO Gastrointestinal Cancers Symposium according to a Sarah Cannon Research Institute media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History